Drug Profile
ACH 126445
Alternative Names: L-OddULatest Information Update: 05 Feb 2020
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals
- Class Antivirals; Nucleosides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Epstein-Barr virus infections; Infectious mononucleosis; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder
Most Recent Events
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 03 Sep 2002 Preclinical trials in Post-transplant lymphoproliferative disorder in USA (unspecified route)
- 03 Sep 2002 Preclinical trials in Infectious mononucleosis in USA (unspecified route)